BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kozhieva M, Naumova N, Alikina T, Boyko A, Vlassov V, Kabilov MR. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity. BMC Microbiol 2019;19:309. [PMID: 31888483 DOI: 10.1186/s12866-019-1685-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Boussamet L, Rajoka MSR, Berthelot L. Microbiota, IgA and Multiple Sclerosis. Microorganisms 2022;10:617. [PMID: 35336190 DOI: 10.3390/microorganisms10030617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Duarte-Silva E, Meuth SG, Peixoto CA. Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment. Front Neurosci 2022;16:885031. [PMID: 35573295 DOI: 10.3389/fnins.2022.885031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Spichak S, Bastiaanssen TFS, Berding K, Vlckova K, Clarke G, Dinan TG, Cryan JF. Mining microbes for mental health: Determining the role of microbial metabolic pathways in human brain health and disease. Neurosci Biobehav Rev 2021;125:698-761. [PMID: 33675857 DOI: 10.1016/j.neubiorev.2021.02.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Faber W, Stolwijk-Swuste J, van Ginkel F, Nachtegaal J, Zoetendal E, Winkels R, Witteman B. Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis-A Systematic Review. J Clin Med 2021;10:1598. [PMID: 33918927 DOI: 10.3390/jcm10081598] [Reference Citation Analysis]
5 Cui C, Ruan Y, Qiu W. Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention. J Clin Neurosci 2020;82:193-9. [PMID: 33257156 DOI: 10.1016/j.jocn.2020.11.011] [Reference Citation Analysis]
6 Kozhieva M, Naumova N, Alikina T, Boyko A, Vlassov V, Kabilov MR. The Core of Gut Life: Firmicutes Profile in Patients with Relapsing-Remitting Multiple Sclerosis. Life (Basel) 2021;11:55. [PMID: 33466726 DOI: 10.3390/life11010055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Levi I, Gurevich M, Perlman G, Magalashvili D, Menascu S, Bar N, Godneva A, Zahavi L, Chermon D, Kosower N, Wolf BC, Malka G, Lotan-Pompan M, Weinberger A, Yirmiya E, Rothschild D, Leviatan S, Tsur A, Didkin M, Dreyer S, Eizikovitz H, Titngi Y, Mayost S, Sonis P, Dolev M, Stern Y, Achiron A, Segal E. Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis. Cell Rep Med 2021;2:100246. [PMID: 33948576 DOI: 10.1016/j.xcrm.2021.100246] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M, Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci 2020;10:E234. [PMID: 32295236 DOI: 10.3390/brainsci10040234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
9 Zhu W, Dykstra K, Zhang L, Xia Z. Gut Microbiome as Potential Therapeutics in Multiple Sclerosis. Curr Treat Options Neurol 2021;23. [DOI: 10.1007/s11940-021-00693-1] [Reference Citation Analysis]
10 Noto D, Miyake S. Gut dysbiosis and multiple sclerosis. Clin Immunol 2020;:108380. [PMID: 32169440 DOI: 10.1016/j.clim.2020.108380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
11 Haase S, Wilck N, Haghikia A, Gold R, Mueller DN, Linker RA. The role of the gut microbiota and microbial metabolites in neuroinflammation. Eur J Immunol 2020;50:1863-70. [PMID: 33188704 DOI: 10.1002/eji.201847807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Volkova A, Ruggles KV. Predictive Metagenomic Analysis of Autoimmune Disease Identifies Robust Autoimmunity and Disease Specific Microbial Signatures. Front Microbiol 2021;12:621310. [PMID: 33746917 DOI: 10.3389/fmicb.2021.621310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zhao H, Yuan L, Zhu D, Sun B, Du J, Wang J. Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis. Pol J Microbiol 2022;71:173-89. [PMID: 35675824 DOI: 10.33073/pjm-2022-016] [Reference Citation Analysis]
14 Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, Anderson MC, De Jager PL, Polgar-Turcsanyi M, Healy BC, Glanz BI, Bakshi R, Chitnis T, Weiner HL. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol 2021;89:1195-211. [PMID: 33876477 DOI: 10.1002/ana.26084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Grigor'eva I, Romanova T, Naumova N, Alikina T, Kuznetsov A, Kabilov M. Gut Microbiome in a Russian Cohort of Pre- and Post-Cholecystectomy Female Patients. J Pers Med 2021;11:294. [PMID: 33921449 DOI: 10.3390/jpm11040294] [Reference Citation Analysis]
16 Plassais J, Gbikpi-Benissan G, Figarol M, Scheperjans F, Gorochov G, Derkinderen P, Cervino ACL. Gut microbiome alpha-diversity is not a marker of Parkinson's disease and multiple sclerosis. Brain Commun 2021;3:fcab113. [PMID: 34704023 DOI: 10.1093/braincomms/fcab113] [Reference Citation Analysis]